Work

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design

Year: 2020

Type: article

Study design: Study Protocol

Source: Future Oncology

DOI: 10.2217/fon-2020-0351

Authors: Nikhil I Khushalani, Adi Diab, Paolo A Ascierto, James Larkin, Shahneen Sandhu, Mario Sznol, Henry B Koon, Anthony Jarkowski, Ming Zhou, Paul Statkevich, William J Geese, Georgina V Long

Institutions: Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, Yale New Haven Hospital, Yale Cancer Center, Yale University, Bristol-Myers Squibb (United States), The University of Sydney, Royal North Shore Hospital, Melanoma Institute Australia

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Bristol-Myers Squibb

OpenAlex ID: W3045601680

FWCI: 1.685

Cites: 26

Cited by: 29

Related to: 10